Table 1.

Study patient characteristics

Patient no.	4-week response	Sex	Age	HCV GT	Viral load, log10 international units/ml			12-week response	Follow-up	Metavir	Weight, kg
					Baseline	4 weeks	12 weeks
1	RR	M	52	3a	7.14	Neg.	Neg.	EVR	SVR	A2/F2	75
2	RR	M	37	3a	4.90	Neg.	Neg.	EVR	SVR	A1/F2	73
3	RR	M	38	1a	6.91	Neg.	Neg.	EVR	EoTR	A2/F1	85
4	RR	M	33	2b	6.27	Neg.	Neg.	EVR	EoTR	A1/F2	57
5	RR	M	48	2b	6.67	Neg.	Neg.	EVR	SVR	A3/F4	110
6	RR	F	53	2a/c	4.95	Neg.	Neg.	EVR	SVR	A3/F3	74
7	RR	M	56	3	5.25	Neg.	Neg.	EVR	EoTR	A3/F4	61
8	RR	M	38	4	4.08	Neg.	Neg.	EVR	Ongoing	A2/F2	69
9	RR	F	50	1b	7.22	3.52	Neg.	EVR	Ongoing	A1/F2	47
10	RR	F	48	1	6.49	3.31	Neg.	EVR	Ongoing	A3/F4	60
11	Non-RR	F	54	3a	4.52	4.08	1.3	EVR	No EoTR	A3/F4	69
12	Non-RR	M	64	1b	6.24	4.83	3.46	EVR	No EoTR	A3/F4	74
13	Non-RR	M	49	4	6.91	5.87	5.22	PNR	-	A3/F4	102
14	Non-RR	M	56	1b	6.89	6.76	6.01	PNR	-	A2/F3	60
15	Non-RR	F	50	1a	7.11	6.58	6.35	PNR	-	A1/F2	77
16	Non-RR	F	47	1a	6.16	5.99	5.52	PNR	-	A2/F2	81

M, male; F, female; GT, genotype.